NCT06304857View on ClinicalTrials.gov

CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL

PHASE3RecruitingINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Breast CancerHeart Failure
Interventions
DRUG

Dapagliflozin

10 mg tablet q.d

DRUG

Placebo

tablet matching dapagliflozin 10 mg q.d

Trial Locations (3)

50-981

RECRUITING

4th Military Clinical Hospital with Polyclinic, Wroclaw

53-413

RECRUITING

Lower Silesian Centre for Oncology, Lung Diseases and Hematology, Wroclaw

04-141

RECRUITING

Military Medical Institute, Warsaw

All Listed Sponsors
lead

4th Military Clinical Hospital with Polyclinic, Poland

OTHER